The Globe and Mail reports in its Friday, Dec. 22, edition that National Bank Financial analyst Zachary Evershed has reiterated his "outperform" recommendation for DRI Healthcare Trust. The Globe's David Leeder writes that Mr. Evershed's unit target soared $6.75 to $18.50, implying an estimated total return of 55 per cent. Analysts on average target the units at $19.76. Mr. Evershed sees "long-term tailwinds driving the pharmaceutical and healthcare space forward." Mr. Evershed says in a note: "DHT sits on a healthy almost $3-billion pipeline of opportunities, and with $766-million deployed since 2021, remains on track to comfortably exceed the $850-million to $900-million targeted by 2025, with no internal bottlenecks which would see the recent elevated pace subside ($391-million year-to-date). In combination with a supportive environment where financing remains in high demand as an increasing number of drugs come to market and biotech companies approach the end of their cash runways, this allows the company to be increasingly selective on only the most accretive deals, with the latest transactions boasting higher IRRs and asymmetric levers (milestone payments) switching from outflows to inflows for DHT."